This Article Full Text Full Text (PDF) All Versions of this Article: 22/12/2099    most recent 01.ATV.0000042456.84190.F0v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mast, A. E. Articles by Dietzen, D. J. Search for Related Content PubMed PubMed Citation Articles by Mast, A. E. Articles by Dietzen, D. J. Related Collections Coagulation Acute coronary syndromes Other diagnostic testing Other Vascular biology

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2002;22:2099.)
© 2002 American Heart Association, Inc.

Thrombosis

Characterization of the Association of Tissue Factor Pathway Inhibitor With Human Placenta

Alan E. Mast; Nayana Acharya; Mark J. Malecha; Connie L. Hall; Dennis J. Dietzen

From the Research and Pathology Services (A.E.M., N.A., M.J.M., D.J.D.), Department of Veterans Affairs, Memphis, Tenn; Department of Pathology (A.E.M., M.J.M., D.J.D.), The University of Tennessee, Memphis, Tenn; and Pritzker Institute of Medical Engineering (C.L.H.), Illinois Institute of Technology, Chicago, Ill.

Correspondence to Alan Mast, Research Service-151, VA Hospital, 1030 Jefferson Ave, Memphis, TN 38104. E-mail alan.mast3{at}med.va.gov

Objective— Tissue factor pathway inhibitor (TFPI) is an endothelial-associated inhibitor of blood coagulation. Because the mechanism for attachment of TFPI to endothelium is not clear, we investigated its association with human placenta.

Methods and Results— Western blots demonstrate that treatment with phosphatidylinositol-specific phospholipase C (PIPLC) removes more placental TFPI than either PBS or heparin, a finding confirmed by immunohistochemistry. The amounts of heparin-releasable and PIPLC-releasable TFPI activity on placental endothelium were measured in placentas from 5 individuals. PIPLC removes >10-fold more TFPI activity from the placental fragments than 10 U/mL heparin and >100-fold more than 1 U/mL heparin. Pretreatment of the placental fragments with PIPLC increases the amount of heparin-releasable TFPI by 3-fold. An antibody specific for the C-terminal region of TFPI recognizes PIPLC-releasable TFPI in Western blots.

Conclusions— GPI-anchored TFPI is the predominant form on placental endothelium. Heparin-releasable TFPI likely represents only a small portion of the total TFPI on endothelium that remains attached to cell-surface glycosaminoglycans after cleavage of the GPI anchor by endogenous enzymes. The predominance of GPI-anchored TFPI suggests that heparin infusion does not significantly redistribute TFPI within the vasculature. The intact C-terminus in GPI-anchored TFPI indicates it is not directly attached to a GPI anchor. Rather, it most likely associates with endothelium by binding to a GPI-anchored protein.

Key Words: tissue factor pathway inhibitor • GPI-anchor • Kunitz

This article has been cited by other articles:

				P. E.R. Ellery, K. Hardy, R. Oostryck, and M. J. Adams Further Insight Into the Heparin-Releasable and Glycosylphosphatidylinositol-Lipid-- Anchored Forms of Tissue Factor Pathway Inhibitor Clinical and Applied Thrombosis/Hemostasis, July 1, 2008; 14(3): 267 - 278. [Abstract] [PDF]

				H. Tang, L. Ivanciu, N. Popescu, G. Peer, E. Hack, C. Lupu, F. B. Taylor Jr, and F. Lupu Sepsis-Induced Coagulation in the Baboon Lung Is Associated with Decreased Tissue Factor Pathway Inhibitor Am. J. Pathol., September 1, 2007; 171(3): 1066 - 1077. [Abstract] [Full Text] [PDF]

				S. A. Maroney, S. L. Haberichter, P. Friese, M. L. Collins, J. P. Ferrel, G. L. Dale, and A. E. Mast Active tissue factor pathway inhibitor is expressed on the surface of coated platelets Blood, March 1, 2007; 109(5): 1931 - 1937. [Abstract] [Full Text] [PDF]

				R. Sood, S. Kalloway, A. E. Mast, C. J. Hillard, and H. Weiler Fetomaternal cross talk in the placental vascular bed: control of coagulation by trophoblast cells Blood, April 15, 2006; 107(8): 3173 - 3180. [Abstract] [Full Text] [PDF]

				C. Lupu, X. Hu, and F. Lupu Caveolin-1 Enhances Tissue Factor Pathway Inhibitor Exposure and Function on the Cell Surface J. Biol. Chem., June 10, 2005; 280(23): 22308 - 22317. [Abstract] [Full Text] [PDF]

				J. Ahamed, M. Belting, and W. Ruf Regulation of tissue factor-induced signaling by endogenous and recombinant tissue factor pathway inhibitor 1 Blood, March 15, 2005; 105(6): 2384 - 2391. [Abstract] [Full Text] [PDF]

				O. Piro and G. J. Broze Jr Role for the Kunitz-3 Domain of Tissue Factor Pathway Inhibitor-{alpha} in Cell Surface Binding Circulation, December 7, 2004; 110(23): 3567 - 3572. [Abstract] [Full Text] [PDF]

				G. Lu, G. J. Broze Jr., and S. Krishnaswamy Formation of Factors IXa and Xa by the Extrinsic Pathway: DIFFERENTIAL REGULATION BY TISSUE FACTOR PATHWAY INHIBITOR AND ANTITHROMBIN III J. Biol. Chem., April 23, 2004; 279(17): 17241 - 17249. [Abstract] [Full Text] [PDF]

				J. Zhang, O. Piro, L. Lu, and G. J. Broze Jr Glycosyl Phosphatidylinositol Anchorage of Tissue Factor Pathway Inhibitor Circulation, August 5, 2003; 108(5): 623 - 627. [Abstract] [Full Text] [PDF]